Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)
Hansoh Pharma re-filed prospectus in April and is targeting a listing by summer. In our previous insight, we covered the company's major products...
978 Views
MabPharma (迈博医药) IPO: Assembled for a Trade?
MabPharma, backed by Chinese private equity investor CDH, is seeking to list in Hong Kong. In this insight, we will discuss the following...
972 Views
HLX02: Innovation Could Overtake
The oncology treatment landscape in China is evolving rapidly as the government has prioritized access to innovative drugs to meet this significant...
704 Views
Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In this insight, we will discuss the following topics: The...
1.3k Views
HK Connect Discovery Weekly: CRRC, Car Inc/UCar (2019-01-25)
In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...
600 Views